Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | Iberdomide + dexamethasone in R/R multiple myeloma

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, presents the results of a study evaluating iberdomide, a cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone in patients with triple-class refractory multiple myeloma or in patients who have been exposed to an anti-BCMA agent (NCT02773030). The overall response rate (ORR) reached 30% in both patient groups and the median progression-free survival (PFS) was three months. Dr Popat explains that in contrast to pomalidomide and lenalidomide, iberdomide is associated with significantly lower rates of non-hematological toxicity. In the future, iberdomide will be evaluated in combination with proteasome inhibitors, monoclonal antibodies and as a maintenance strategy post-transplantation. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.